| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | dabrafenib | CTRPv2 | pan-cancer | AAC | 0.32 | 6e-13 |
| mRNA | IU1 | CTRPv2 | pan-cancer | AAC | 0.25 | 6e-12 |
| mRNA | PLX4720 | CTRPv2 | pan-cancer | AAC | 0.21 | 9e-10 |
| mRNA | BRD-K84807411 | CTRPv2 | pan-cancer | AAC | 0.43 | 1e-09 |
| mRNA | CIL55A | CTRPv2 | pan-cancer | AAC | 0.29 | 2e-09 |
| mRNA | salermide:PLX-4032 (12:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.2 | 4e-08 |
| mRNA | GDC-0879 | CTRPv2 | pan-cancer | AAC | 0.17 | 4e-07 |
| mRNA | BRD-K41334119 | CTRPv2 | pan-cancer | AAC | 0.36 | 4e-07 |
| mRNA | BRD-K27224038 | CTRPv2 | pan-cancer | AAC | 0.35 | 1e-06 |
| mRNA | tacrolimus | CTRPv2 | pan-cancer | AAC | 0.16 | 3e-06 |